Skip to main content

Table 3 Drug-pathway association in the DTPN of HER2 subtype

From: In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition

Drug Pathway nNE and PCI (vs NE = 0.3492)
Fluoracil Salvage pathways of pyrimidine deoxyribonucleotides 0.3482 (PCI 0.27%)
Docetaxel Epithelial adherens junction signaling 0.3485 (PCI 0.17%)
Fulvestrant Bladder cancer signaling 0.3473 (PCI 0.51%)
Methotrexate Salvage pathways of pyrimidine deoxyribonucleotides 0.3482 (PCI 0.27%)
Tamoxifen Human embryonic stem cell pluripotency (1); regulation of the epithelial-mesenchymal transition (2) (1) 0.3464 (PCI 0.78%)
(2) 0.3490 (PCI 0.02%)
(1–2) 0.3462 (PCI 0.84%)